Vascodagama Online Journal

Malaria Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies – Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics

 Breaking News
  • No posts were found

Malaria Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies – Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics

April 27
23:25 2023
Malaria Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies - Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics
DelveInsight’s “Malaria Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Malaria.

DelveInsight’s “Malaria Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Malaria, historical and forecasted epidemiology as well as the Malaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Malaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Malaria Market Forecast

 

Some of the key facts of the Malaria Market Report: 

  • The Malaria market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In November 2022, The decision to advance ganaplacide/lumefantrine-solid dispersion formulation (SDF) into Phase III development for the treatment of individuals with acute, uncomplicated Plasmodium falciparum malaria is announced by Novartis and MMV. A new formulation of lumefantrine that is designed for once-daily dosing is mixed with the novel drug ganaplacide, which has a new mechanism of action. This combination has the ability to stop the spread of the malaria parasite as well as eradicate malaria infections, particularly those caused by artemisinin-resistant strains. The medicine is being developed with scientific and financial support from MMV and their partners
  • In November 2022, Dr. Jake Kurtis, Scientific Co-Founder of Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA), will deliver ground-breaking research findings at this week’s Annual Meeting of The American Society of Tropical Medicine and Hygiene. These results, which could pave the way for an entirely new class of antimalarial medications at a time when artemisinin-based therapies are starting to lose their effectiveness, are timely. Since the blood stage of the malaria lifecycle is where all clinical illness and mortality occur, Ocean’s novel method has the potential to be substantially more effective than vaccines that target other stages. This small molecule medication programme will be a major emphasis of Ocean Biomedical’s development pipeline in 2023, along with the associated vaccine programme
  • According to the WHO World Malaria Report 2021, globally, there were an estimated 241 million malaria cases in 2020 in 85 malaria endemic countries (including the territory of French Guiana), increasing from 227 million in 2019, with most of this increase coming from countries in the WHO African Region
  • As per WHO World Malaria Report 2021, malaria case incidence (i.e. cases per 1000 population at risk) reduced from 81 in 2000 to 59 in 2015 and 56 in 2019, before increasing again to 59 in 2020
  • The dynamics of Malaria therapeutics market is further expected to increase by the major drivers such as rising cases, technological advancements, and upcoming therapies in the forecast period [2022-2032]
  • Key Malaria Companies: Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Ginkgo Bioworks, Sumitomo Pharma, MYMETICS, Merck KGaA, BioNTech, Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd, Novavax, Artificial Cell Technologies, Inc., Nobelpharma Co., Ltd., ExpreS2ion Biotechnologies, Blue Water Vaccines, Inc.,  Eisai Co. Ltd.,  Ocean Biomedical, Lumen Bioscience, Modus Therapeutics, Atreca, AliquantumRX Inc., Carna Biosciences, CureVac AG, EpiVax, and others
  • Key Malaria Therapies: Ganaplacide/lumefantrine-(SDF), Cipargamin (KAE609), Azithromycin plus Chloroquine, KAE609, PfSPZ Vaccine, Ganaplacide + lumefantrine, GSK3437949A, Cipargamin, LYN-163, BNT165b, MSP3-CRM-Vac4All, GSK3772701, TP-05, GEO-MM02, and others
  • The Malaria market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Malaria pipeline products will significantly revolutionize the Malaria market dynamics.

 

Malaria Overview

Malaria disease can be categorized as uncomplicated or severe (complicated). Uncomplicated malaria can be referred to as symptomatic malaria parasitaemia with no signs of severity and/or evidence of vitalorgan dysfunction. Uncomplicated malaria can be caused by all Plasmodium species. Severe malaria occurs when infections are complicated by serious organ failures or abnormalities in the patient’s blood or metabolism.

 

Get a Free sample for the Malaria Market Report –

https://www.delveinsight.com/sample-request/plasmodium-vivax-malaria-market

 

Malaria Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Malaria Epidemiology Segmentation:

The Malaria market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Malaria
  • Prevalent Cases of Malaria by severity
  • Gender-specific Prevalence of Malaria
  • Diagnosed Cases of Episodic and Chronic Malaria

 

Download the report to understand which factors are driving Malaria epidemiology trends @ Malaria Epidemiology Forecast

 

Malaria Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Malaria market or expected to get launched during the study period. The analysis covers Malaria market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Malaria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Malaria Therapies and Key Companies

  • Ganaplacide/lumefantrine-(SDF): Novartis/MMV
  • Cipargamin (KAE609): Novartis
  • Azithromycin plus Chloroquine: Pfizer
  • KAE609: Novartis
  • PfSPZ Vaccine: Sanaria
  • Ganaplacide + lumefantrine: Medicines for Malaria Venture/Novartis
  • GSK3437949A: GlaxoSmithKline
  • Cipargamin: Novartis
  • LYN-163: Lyndra Therapeutics
  • BNT165b1: BioNTech SE
  • MSP3-CRM-Vac4All: Vac4All
  • GSK3772701: GlaxoSmithKline
  • TP-05: Tarsus Pharmaceuticals
  • GEO-MM02: GeoVax

 

Discover more about therapies set to grab major Malaria market share @ Malaria Treatment Market

 

Scope of the Malaria Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Malaria Companies: Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Ginkgo Bioworks, Sumitomo Pharma, MYMETICS, Merck KGaA, BioNTech, Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd, Novavax, Artificial Cell Technologies, Inc., Nobelpharma Co., Ltd., ExpreS2ion Biotechnologies, Blue Water Vaccines, Inc.,  Eisai Co. Ltd.,  Ocean Biomedical, Lumen Bioscience, Modus Therapeutics, Atreca, AliquantumRX Inc., Carna Biosciences, CureVac AG, EpiVax, and others
  • Key Malaria Therapies: Ganaplacide/lumefantrine-(SDF), Cipargamin (KAE609), Azithromycin plus Chloroquine, KAE609, PfSPZ Vaccine, Ganaplacide + lumefantrine, GSK3437949A, Cipargamin, LYN-163, BNT165b, MSP3-CRM-Vac4All, GSK3772701, TP-05, GEO-MM02, and others
  • Malaria Therapeutic Assessment: Malaria current marketed and Malaria emerging therapies
  • Malaria Market Dynamics: Malaria market drivers and Malaria market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Malaria Unmet Needs, KOL’s views, Analyst’s views, Malaria Market Access and Reimbursement 

 

To know more about Malaria companies working in the treatment market, visit @ Malaria Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Malaria Market Report Introduction

2. Executive Summary for Malaria

3. SWOT analysis of Malaria

4. Malaria Patient Share (%) Overview at a Glance

5. Malaria Market Overview at a Glance

6. Malaria Disease Background and Overview

7. Malaria Epidemiology and Patient Population

8. Country-Specific Patient Population of Malaria 

9. Malaria Current Treatment and Medical Practices

10. Malaria Unmet Needs

11. Malaria Emerging Therapies

12. Malaria Market Outlook

13. Country-Wise Malaria Market Analysis (2019–2032)

14. Malaria Market Access and Reimbursement of Therapies

15. Malaria Market Drivers

16. Malaria Market Barriers

17.  Malaria Appendix

18. Malaria Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories